Peter O'Donnell to United States
This is a "connection" page, showing publications Peter O'Donnell has written about United States.
Connection Strength
0.294
-
Preferred Treatment Sequencing for Metastatic Urothelial Carcinoma (mUC) in the Era of Perioperative and First-Line (1L) Checkpoint Inhibitor: Results From a National Survey of Genitourinary Oncologists. Clin Genitourin Cancer. 2026 Mar; 24(2):102487.
Score: 0.088
-
A National Study Among Diverse US Populations of Exposure to Prescription Medications with Evidence-Based Pharmacogenomic Information. Clin Pharmacol Ther. 2025 06; 117(6):1793-1802.
Score: 0.083
-
Patient Perceptions of Care as Influenced by a Large Institutional Pharmacogenomic Implementation Program. Clin Pharmacol Ther. 2017 07; 102(1):106-114.
Score: 0.048
-
Disease-drug database for pharmacogenomic-based prescribing. Clin Pharmacol Ther. 2016 08; 100(2):179-90.
Score: 0.045
-
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems. Clin Pharmacol Ther. 2017 Sep; 102(3):502-510.
Score: 0.012
-
Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: a report from the Bladder Cancer Advocacy Network Clinical Trials Working Group. Cancer. 2013 Jun 01; 119(11):1994-8.
Score: 0.009
-
A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study. Prostate Cancer Prostatic Dis. 2012 Mar; 15(1):87-92.
Score: 0.008